Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the activation of autoreactive B lymphocytes, which are supposed to carry aberrant signal transduction after the stimulation of B-cell receptor (BCR). To investigate abnormalities in BCR-mediated signaling pathway in lupus B lymphocytes, we analyzed HS1, a molecule downstream of BCR, in 80 Japanese SLE patients. We identified 37 amino acid deletion of HS1 in a 25-year-old female patient, and the aberrant HS1 lacked a part of a functional motif. Analysis of genomic DNA revealed that the aberrant HS1 was caused by exon skipping. Family study showed that the patient as well as her father and sister are heterozygous for the abnormality. WEHI-231 cell, a mouse B cell line, transfected with the aberrant HS1 displayed a significantly increased cell death upon cross-linking of BCR. Additionally, peripheral B lymphocytes from the patient exerted increased apoptosis after BCR stimulation compared to those from control SLE patients. These data suggest that the aberrant HS1 molecule may transmit an accelerated signal after BCR stimulation and may play a role in the activation of autoreactive B lymphocytes.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease associated with multiple genetic and environmental factors. [1] [2] [3] [4] [5] [6] This disease is characterized by the production of autoantibodies and subsequent immune complex deposition in several organ systems, and which leads to tissue injury. [1] [2] [3] [4] [5] [6] [7] These autoantibodies are produced by autoreactive B lymphocytes. 8 Previously, they have been considered to be innocent bystanders, which are activated secondarily by autoreactive T lymphocytes and/or uncommon immune environment, such as abnormal cytokine production or the overproduction of polyclonal B-cell activators. [8] [9] [10] [11] [12] However, recent reports suggest that they are intrinsically defective. [13] [14] [15] [16] [17] B-cell receptor (BCR) is composed of membrane immunoglobulin and heterodimers of Iga and Igb. 18, 19 After the stimulation of BCR, one of the initial intracellular signaling events is the activation of nonreceptor-type protein tyrosine kinases, including Lyn and Syk. 20, 21 These kinases rapidly phosphorylate tyrosine residues of a number of intracellular substrates, such as Vav, phospholipase C g, and HS1, and consequently lead to cell proliferation, differentiation, or apoptosis. 20, 21 This pathway is also negatively regulated by co-receptors such as Fcg receptor II and CD22, which induce a recruitment of phosphatases to BCR-complex. 22 BCR-mediated signals play an important role in the maintenance of both central and peripheral tolerance of B-cell lineage, 23, 24 hence, it is possible that intrinsically abnormal BCR-mediated signaling transduction contributes to the breakdown of self-tolerance in a certain subset of human SLE. Indeed, Lyn-deficient mice demonstrated the activation of autoreactive B lymphocytes and subsequent SLE-like symptoms, such as the production of anti-double-strand DNA antibody, splenomegaly and glomerulonephritis. 25, 26 Moreover, it is shown that lupus B lymphocytes exhibit aberrant BCRmediated signal transduction. 13 These data prompted us to investigate BCR-associated signaling molecules in SLE patients. Although there was no obvious defect in Lyn, we identified a molecular abnormality in HS1 in one patient out of 80 Japanese SLE patients. The aberrant HS1 demonstrated a 37 amino acid deletion, which was caused by an exon skipping. Considering that HS1 is one of the major substrates of Lyn tyrosine kinase and is known to play a role in BCR-mediated signal transduction, [27] [28] [29] [30] [31] [32] functional study was performed. WEHI-231 cell transfected with the aberrant HS1 molecule showed more potent ability to induce BCR-mediated cell death than wild-type HS1-transfectant. Additionally, BCR-stimulation of the patient's peripheral B lymphocytes resulted in increased degree of apoptosis compared with those of control SLE patients. These data suggest that the aberrant HS1 molecule may give rise to an accelerated signal from BCR, which may cause a lowered threshold of BCRmediated signaling and an activation of peripheral anergic autoantibody-producing B cells. Thus, the present study implies that HS1 may be one of the genetic factors for autoantibody production in SLE patients.
Results
Detection of aberrant HS1 protein in a patient with SLE First, we studied the expression of HS1 protein in SLE patients. PBMC separated from SLE patients were lysed, and Western blot analysis was performed using these cell lysates and anti-HS1 polyclonal antibody. Among 80 patients analyzed, there was no difference in the amount of HS1 protein. However, in one patient, a smaller band was detected in addition to the band of wild-type HS1, at equivalent expression level (Figure 1 ). The aberrant band was also observed when using anti-HS1 monoclonal antibody (data not shown). These data showed that a defect of HS1 protein appeared to be present in this patient. Additionally, we assessed the expression of Lyn protein, and found no abnormalities in the size or the amount of Lyn among these patients (data not shown).
Detection of transcripts encoding the aberrant HS1 in the patient
To ensure that the aberrant HS1 protein is expressed by a defect of HS1 mRNA, HS1 cDNA from the patient was analyzed by RT-PCR method, using forward and reverse primers located in the 5 0 and 3 0 ends of the molecule (described as 20F and 1659R, respectively, in Patients and methods). As shown in Figure 2a , products generated from the patient's RNA yielded two bands of approximately equal intensity, whereas the lower band was absent in controls. Also, RT-PCR products obtained by another primer pairs that are located in the coding region of HS1 (described as 254F and 826R in Patients and methods) revealed an aberrant band pattern (Figure 2b ). These data clarified that HS1 deletion is already present at transcriptional level.
Additionally, no aberrant HS1 mRNA was detected in 80 healthy controls when assessed by RT-PCR method (data not shown).
Identification of the deleted region of HS1 cDNA in the patient To clarify the deleted sequences, the aberrant band was excised from agarose gel, purified, and directly sequenced. As shown in Figure 3a , the aberrant fragment lacked 111 bp, which encodes 37 amino acid sequence within three and one-half times repeat of 37 amino acid, a functional motif of HS1 protein (Figure 3b) .
Because the deleted sequences were 92% identical to those of exon 7 of murine HS1 gene, 28 it is likely that the deleted sequences corresponded with those of a certain exon. We determined genomic sequences of human HS1 around the 111-bp fragment by inverse PCR method. As expected, we found that the sequences of the 5 0 and 3 0 end of the 111-bp fragment as well as their flanking genome sequence are completely matched with the exon-intron consensus sequence.
33,34
Therefore, we Figure 1 Expression of HS1 in SLE patients and a control. PBMC from SLE patients and a control donor were lysed, and proteins were separated by 8% SDS-PAGE. Then, proteins were electrophoretically transferred to nitrocellulose, and the membrane was blotted with anti-human HS1 polyclonal antibody. Bands were visualized by enhanced chemiluminescence. In addition to an expected size band of HS1, an aberrant band was also detected in an SLE patient (lane 3), which was not detected in the other SLE patients (lanes 1-2) and a control (lane C). RNA isolated from PBMC from the patient and an unrelated control was reverse transcribed and cDNA was used in subsequent PCR reactions. Primers were derived from the published human sequences and are located within 5 0 and 3 0 untranslated regions of the HS1 cDNA. 27 HS1 cDNA was amplified using the primer pair, and products were analyzed by agarose gel electrophoresis. In addition to the expected band (1640 bp) of wild-type HS1 cDNA, a shorter band was detected only in the patient (P) (arrowed as aberrant HS1). (b) RT-PCR were conducted with another primer pair set within the coding region of HS1 cDNA (sense and antisense primer were located at 254-274 and 809-826 of reported HS1 cDNA sequence, 27 respectively), and products were analyzed by agarose gel electrophoresis. In addition to the expected band (573 bp), a shorter band was again detected in the patient (P) (arrowed as aberrant HS1), whereas not detected in a control (C).
concluded that the aberrant HS1 molecule lacks sequences that correspond with a certain exon. Because the exon numbers have not been confirmed in human HS1 gene, we called the skipped exon as exon A. Since the wild-type and the aberrant HS1 protein were detected at the almost equivalent level by Western blotting in the patient (Figure 1 ), it is highly probable that one allele encodes wild-type HS1 and the another encodes HS1 lacking exon A (HS1 Dexon A), which is caused by exon skipping, in the patient.
Exon skipping is mostly caused by the mutation in the flanking region of the skipped exon. [33] [34] [35] To detect a genomic DNA mutation responsible for the skipping of HS1 exon A, we synthesized primers for HS1 exon Aspecific PCR, and conducted PCR/SSCP analysis for the patient and normal controls. However, no DNA fragment showed variations on electrophoresis (data not shown). Furthermore, direct nucleotide sequencing revealed no nucleotide mutation within exon A and its flanking intron sequences of 50 bp (data not shown).
Detection of HS1 Dexon A in her father and sister Since we found no mutations in the flanking genomic sequence of HS1 exon A, we performed a family study by Western blot analysis to investigate whether a germline mutation causes the skipping of HS1 exon A. As expected, the band corresponded to HS1 Dexon A was detected not only in the patient but also in her father and sister ( Figure 4 ). These data clearly demonstrated that the skipping of exon A is inherited among these family members, and clearly showed that HS1 Dexon A is produced by a germline mutation. Clinically, antinuclear antibody was detected in her sister, although her father and sister did not fulfill the classification criteria for SLE. 36 Functional analysis of HS1 Dexon A BCR-stimulation induces cell death in WEHI-231 cell line by the activation of both apoptotic and necrotic pathway. 37 As HS1 is shown to participate in this cell death signal, [29] [30] [31] [32] we estimated the effect of HS1 Dexon A on the BCR-mediated cell death system by using WEHI-231 cells. We transfected HS1 wild-type cDNA, HS1 Dexon A cDNA and control pCXN-2 vector into WEHI-231 cells. Three clones from each transfection were established. The expression of the transfected cDNA was assessed by Western blot analysis. Each stable transformant expresses comparable amount of protein encoded by the transfected cDNA to endogeneous HS1 of WEHI-231 cells (data not shown). Therefore, we used clones transfected with wild-type HS1 as models for homogenous expression of wild-type HS1, and clones transfected with HS1 Dexon as models for heterogeneous expression of wildtype HS1 and HS1 Dexon A. Each transfectant and wildtype WEHI-231 cells were left unstimulated or were Figure 3 (a) Nucleotide sequencing of aberrant HS1 cDNA. A shorter band detected in RT-PCR was excised from the agarose gel, and directly sequenced. A 111-bp deletion corresponding to the nucleotide 510-620 of the reported HS1 cDNA sequence 27 was identified. The lacked sequences were 92% identical to those of exon 7 of murine HS1 gene. 28 (b) Schematic representation of the structure of HS1 wild-type and HS1 Dexon A. The numbers at the bottom refer to amino acid position, and asterisks show tyrosine residues. The amino acid sequence of HS1 contains a variety of structurally significant motifs, including an N-terminal basic motif (blackened), followed by three and one-half times repeats of a unique 37 amino acid residue motif (shaded), a long a-helix structure localized to the C-terminal central moiety (hatched), and an Src-homology 3 (SH3) domain at the C-terminus (striped). HS1 Dexon A lacks the third repeat of the 37 amino motif that can form a helix-turn-helix structure frequently found in DNA binding proteins. Figure 4 Familial study of HS1 expression performed by Western blot analysis. PBMC from the patient, her father, mother, sister, and a control were lysed, and proteins were separated by 8% SDS-PAGE. Then, proteins were transferred to nitrocellulose, and the membrane was blotted with anti-human HS1 monoclonal antibody. Bands were visualized by enhanced chemiluminescence. In addition to bands corresponding to wild-type HS1, bands corresponding to HS1 Dexon A were detected in the SLE patient, her father and sister, while they were not detected in her mother and a control. stimulated with 1 mg/ml of goat F(ab 0 ) 2 anti-mouse IgM antibody for 48 h, and we assessed cell death by propidium iodide staining, which can detect both apoptotic and necrotic cells. Cells were stained with 1 mg/ml of propidium iodide, and the percentages of propidium iodide-positive (dead) and -negative (live) cells were analyzed with FACScan (Table 1) .
Although the percentages of propidium iodide-positive cells were not different among unstimulated groups, they were significantly increased after BCR stimulation in WEHI-231 cells transfected with HS1 wild-type and HS1 Dexon A, when compared with wild-type cells or mock-transfected cells (Po0.01). These results confirmed that HS1 is a potent mediator of BCR-induced cell death in WEHI-231 cells. Furthermore, there was also a significant increase in the percentage of propidium iodide-positive cells after BCR cross-linking in HS1 Dexon A-transfected cells compared with those transfected with HS1 wild-type (Po0.05). Representative data are shown in Figure 5 . These data clearly indicate that HS1 Dexon A has more potent ability to induce BCR-mediated cell death than wild-type HS1 molecule in WEHI-231 cells. It is thus suggested that HS1 Dexon A transduces increased signal(s) from BCR and consequently alters the cellular response of B lymphocytes.
Functional analysis of the patient's B lymphocytes
Since the functional analysis shows that HS1 Dexon A transduces enhanced signal(s) from BCR, which may consequently change the cellular reaction after BCR stimulation, we assessed BCR-induced cellular response of B lymphocytes from the patient. First, we 38 Therefore, it is likely that HS1 Dexon A transduced enhanced BCRmediated signal that is equivalent to that induced by the extensive cross-linking of BCR, thereby resulting in the increased apoptosis of the B lymphocytes of the patient carrying HS1 Dexon A. Next, we assessed BCR-induced activation of peripheral B lymphocytes by the measurement of the expression levels of CD69 after IgM crosslinking, however, there was no difference between our patient and control SLE patients (data not shown).
Discussion
In the present study, we identified an aberrant HS1 molecule, which is likely to be associated with hyperreactivity to BCR stimulation, in a patient with SLE. The splicing variant, HS1 Dexon A, lacks one of the three and a half repeats of 37 amino acids in the N-terminal region of HS1, and is carried heterozygously by the patient, as clarified by the family study. Transfection of HS1 Dexon A into WEHI-231 cells revealed that HS1 Dexon A is more potent for BCR-induced cell death than wild-type HS1. Moreover, BCR stimulation of the patient's peripheral B lymphocytes resulted in increased level of apoptosis compared to those from control SLE patients. Therefore, it is assumed that HS1 Dexon A transmits increased signal(s) after BCR stimulation and subsequently changes the cellular response of B lymphocytes quantitatively or qualitatively, and that may contribute to the pathogenesis of SLE. To our knowledge, this is the first report describing an association between SLE and an abnormality in the BCR-related signaling molecule. Although Lyn, the molecule that is directly associated with BCR and exerts tyrosine phosphorylation of the downstream molecules including HS1, did not have any abnormalities in our patients, our study might imply that BCR-related signaling molecules other than HS1, such as phospholipase C g and Vav, might also be involved in the pathogenesis of SLE.
HS1 is a 75-kDa protein found in the cytoplasm and to a lesser extent in the nucleus of essentially all hematopoietic cells. 27 The amino acid sequence of HS1 contains a variety of structurally significant motifs, 27 including three and one-half times repeats of a unique 37 amino acid residue-motif in the N-terminal region that can form a helix-turn-helix structure frequently found in the DNA binding domain of various transcriptional factors, 39 followed by an acidic a-helix region localized in the central moiety, and an SH3 domain at its C-terminus (Figure 3b ). After BCR cross-linking, HS1 is rapidly phosphorylated synergistically by Lyn and Syk, 40 translocates to the nucleus, and induces B-cell response. 32 For instance, HS1 has been shown to play a role in BCRmediated cell death of WEHI-231 B lymphoma cell line, [30] [31] [32] which has been used as a model for immature B cells. 41, 42 A recent report shows that the stimulation of BCR activates both apoptotic and necrotic pathway in WEHI-231 cells; 37 however, it is unclear in which pathway HS1 participates. Therefore, we transfected HS1 wild-type and HS1 Dexon A into WEHI-231 cells, and assessed how HS1 Dexon A affects BCR-mediated signal transduction by comparing propidium iodide-positive cells, which included both apoptotic and necrotic cells, among the transfectants. Surprisingly, we found that HS1 Dexon A has stronger activity to induce cell death after BCR stimuli than wild-type HS1. This result indicates that the HS1 Dexon A transduces signal(s) from BCR in an exceeding way, which may cause a lowered threshold of BCR-mediated signaling. HS1 Dexon A lacks 37 amino acids, which corresponds to one of the three and a half amino acid repeats. 27 These sequences are closely related to HS1 binding to phosphatidylinositol 4,5-biphosphate and F-actin in NIH313 cell. 43 Since F-actin localizes in cytoplasm, 44 it is probable that HS1 Dexon A reduces its binding activity to F-actin, and thereby easily translocates from cytoplasm to nucleus upon BCR stimulation, and consequently transfers accelerated signal(s) that can alter cellular response quantitatively or qualitatively.
The accelerated BCR-mediated signal(s) is likely to change the cellular reaction of peripheral B lymphocytes. Peripheral B lymphocytes are activated by limited cross-linking of BCR, whereas they exert apoptosis by extensive cross-linking of BCR.
38
HS1 is suggested to participate in BCR-associated signaling pathway of peripheral B lymphocytes, because HS1 deficient mice show impaired antibody production and proliferative response of splenic B cells after BCR cross-linking. 29 We revealed that our patient's peripheral B lymphocytes underwent apoptosis by limited cross-linking of BCR. This result suggests that HS1 Dexon A transmits accelerated signal(s) from BCR, 38 which is equivalent to the signal mediated by extensive BCR cross-linking in normal B lymphocytes. Such enhanced signal(s) is likely to reactivate anergic autoreactive B lymphocytes in periphery. Unlike common peripheral B lymphocytes, peripheral anergic autoreactive B lymphocytes show no response by limited cross-linking of BCR; however, they are activated by extensive cross-linking of BCR. 45, 46 Since HS1 Dexon A transmits enhanced signal(s) from BCR, it is probable that the peripheral anergic autoreactive B lymphocytes in our patient are reactivated by a normal 
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Aberrant HS1 in SLE T Sawabe et al extent of BCR stimulation, begin to produce autoantibodies, and consequently lead to the development of SLE. Alternatively, the accelerated BCR-mediated signal(s) may be associated with the development of SLE by the increased supply of autoantigens. BCR stimulation induces apoptosis in immature B lymphocytes, such as WEHI-231 cells. Recent reports suggest that proteins degenerated during apoptosis can promote the production of autoantibodies frequently found in SLE. [47] [48] [49] [50] Moreover, autoantigens from apoptotic bodies were proven to react with autoantibodies, resulting in the tissue deposition of immune complex. 51 These findings suggest that apoptotic bodies serve as reservoirs of autoantigens in SLE. As shown in WEHI-231 cells, HS1 Dexon A transmits accelerated signal(s) from BCR, which results in increased cell death in immature B lymphocytes ( Figure 5 ). Furthermore, our patient's peripheral B lymphocytes were more prone to exert apoptosis upon stimulation of BCR. Since apoptosis of B-cell lineage is one of the major parts of apoptosis in whole human body, it is suggested that accelerated signal(s) from BCR transduced by HS1 Dexon A result in the increase of apoptotic bodies and the persistence of autoantigens, which possibly leads to the development of SLE.
There are two issues to be discussed as for the pathogenic role of HS1 Dexon A to the development of SLE: (1) her father and sister who also carry HS1 Dexon A have not developed SLE and (2) the expression of HS1 Dexon A is detected in only one patient out of 80 SLE cases. However, these findings are consistent with the heterogeneity of SLE. SLE is a polygenic disease triggered by multiple genetic and environmental factors, and single gene locus mutation cannot induce the development of SLE. [1] [2] [3] [4] Therefore, our patient must have developed SLE in combination with many factors including HS1 Dexon A, whereas her father and sister have not developed SLE because of possible losses of other factors to trigger SLE. Similarly, the remaining 79 patients developed SLE by multiple factors other than HS1 aberration. Thus, HS1 Dexon A contributes to the development of SLE in a limited subset of patients. Nevertheless, the significance of HS1 Dexon A cannot be ignored, since our findings clearly demonstrate that HS1 Dexon A has a potential role in the development of SLE through hyperreactivity to BCR stimulation. Taken together, we concluded that HS1 aberration, such as HS1 Dexon A, is one of the genetic factors for the development of SLE. Indeed, we identified a genetic polymorphism of HS1 gene, which is significantly predominant in SLE patients (Otsuka et al, manuscript in preparation). Additionally, the fact that HS1 Dexon A is not expressed in 80 normal controls also supports its pathogenic role for SLE.
The results of the family study of the patient supported the view that an abnormality in HS1 genomic DNA causes the skipping of exon A; however, we did not find any mutation around exon A either by exon-specific PCR/SSCP or direct sequencing. Aberrant splicing is mostly caused by the mutation at the splicing consensus sequence of exon-intron boundary, and, to a lesser extent, by a point mutation within the skipped exon. [33] [34] [35] [52] [53] [54] [55] However, there are several reports of exon skipping without any mutations in the sequence around the skipped exon. [56] [57] [58] [59] [60] Besides, a mutation in an intron away from an exon-intron boundary results in a defect in splicing. 61 We are now analyzing the complete sequences of HS1 genomic DNA of the patient's family.
In conclusion, we found an aberrant HS1 molecule, probably caused by germline mutation, was expressed in an SLE patient. Functional study demonstrated that the aberrant molecule has more potent ability to transfer signal(s) from BCR than wild-type molecule and consequently induces hyperreactivity to BCR stimulation. In the patient, accelerated BCR-mediated signal caused by the aberrant HS1 is supposed to be associated with the lowered threshold of BCR-mediated signaling, which may cause the activation of autoantibody-producing B cells and the development of SLE. This is the first report describing that an aberrant BCR-associated signaling molecule may play a role in the development of SLE. Our present study provides new insights for the study of the pathogenesis of SLE.
Patients and methods

Patients
Eighty SLE patients (75 females, 5 males) were enrolled in this study. All patients were Japanese, and fulfilled at least four of the 11 revised criteria of the American Rheumatism Association for the classification of SLE. 36 Their ages ranged from 17 to 78 years (mean 7 s.d. ¼ 42.6 7 13.8).
Clinical course of the patient
The patient in whom aberrant HS1 was detected was a 25-year-old Japanese female. In May, 1991 (when she was 19 years old), she developed periods of slight fever, general fatigue, and malar rash. She visited a local hospital and was found to have proteinuria and thrombocytopenia. On July 31, she admitted to our hospital for the evaluation of these findings. She had histories of atopic dermatitis, allergic rhinitis, and adenoidectomy. On admission, she presented malar rash and photosensitivity. Urinalysis revealed marked proteinuria (1.68 g/day). She had a leukocyte count of 3800/ml, erythrocyte count of 4.28 Â 10 6 /ml, hemoglobin value of 13.1 g/dl, hematocrit of 42.0%, and platelet count of 79 Â 10 3 /ml. Total protein was 6.0 g/dl, albumin was 3.3 g/dl, blood urea nitrogen was 14 mg/dl, and creatinine was 0.6 mg/dl. Her serum was positive for antinuclear antibody (320 titer, homogeneous and speckled pattern). Immunological study showed IgG of 1363 mg/ dl, IgA of 166 mg/dl, IgM of 153 mg/dl, 50% hemolytic unit of complement (CH50) of 16 U/ml, complement 3 of 50 mg/dl, complement 4 of 14 mg/dl, and anti-doublestrand DNA antibody of 10 IU/ml. Kidney biopsy revealed membranous glomerulonephritis. She was given a diagnosis of SLE, and was successfully treated with dipyridamole and prednisolone (starting from 40 mg/day), which was tapered to 5 mg/day without flare up. When the blood samples were taken, the patient had been in inactive state for 5 years.
Preparation of cells PBMC of the subjects were separated from heparinized venous blood by Ficoll-Hypaque density gradient centrifugation (Organon Teknika Corp., Westchester, PA, USA). WEHI-231 murine B-lymphoma cells were kindly provided by Dr T Tsubata. Cells were cultured at 371C in a humidified atmosphere with 5% CO 2 , in RPMI1640 supplemented with 10% fetal calf serum (ICN Biomedicals Inc., Irvine, CA, USA), 5 mM 2-mercaptoethanol (2-ME), 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Antibodies
The following antibodies were purchased from the indicated companies: anti-human Lyn monoclonal antibody (Wako Pure Chemical Industries, Ltd., Osaka, Japan), anti-human HS1 monoclonal antibody (Medical & Biological Laboratories, Co. Ltd., Nagoya, Japan), peroxidase-conjugated anti-mouse IgG (Southern Biotechnology Associates, Inc., Birmingham, AL, USA), peroxidase-conjugated anti-rabbit IgG (Amersham Corp., Arlington Heights, IL, USA), affinity-purified goat F(ab 0 ) 2 anti-mouse IgM antibody (Cappel; ICN Pharmaceuticals, Aurora, OH, USA), goat F(ab 0 ) 2 anti-human IgM antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA), FITC-conjugated anti-CD69 antibody (Ancell Corporation, Bayport, MN, USA), PE-conjugated anti-CD19 antibody (Pharmingen, Inc., San Diego, CA, USA), cytochrome-conjugated anti-CD19 antibody (Pharmingen, Inc.), FITC-conjugated anti-Anexin V antibody (Trevigen, Inc., Gaithersburg, MD, USA). Anti-HS1 antibody was synthesized as described previously. 29 Western blot analysis Five million PBMC were lysed in 100 ml of 1X SDS-PAGE sample buffer (62.5 mM. Tris-HCl (pH 7.5), 2% SDS, 10% glycerol, 5% 2-ME, and 0.01% bromophenol blue) and sonicated with SONIFIER 250 (Branson Ultrasonics Corporation, Danbury, CT, USA). The lysates were cleared by centrifugation, and 5 ml of each of them were loaded onto an 8% of SDS-polyacrylamide gel. After SDS-PAGE, separated proteins were electrotransferred on a nitrocellulose filter (Bio-Rad Laboratories Inc., Hercules, CA, USA) by the semi-dry method. The membranes were incubated for 1 h in Tween 20-Tris-buffered saline (T-TBS) (20 mM Tris, 150 mM NaCl, 0.05% Tween 20 (pH 8.0)) containing 5% non-fat milk and then washed. Anti-Lyn antibody or anti-HS1 antibody was added and incubated for 2 h at room temperature. After washing with T-TBS, peroxidase-conjugated secondary antibody was added for 2 h at room temperature. Nitrocellulose sheets were then washed in T-TBS, and binding of second antibody was visualized with the enhanced chemiluminescence system (ECL, Amersham Corp.).
RT-PCR analysis
Total RNA was extracted from PBMC by guanidium isothiocyanate/phenol method (Isogen; Nippon Gene Co., Ltd., Toyama, Japan). Single-strand cDNA was synthesized by RT starting from 1 mg of total RNA, according to the manufacturer's recommendation (Pharmacia Biotech Inc., Piscataway, NJ, USA). Primers for RT-PCR were set on the basis of the human HS1 cDNA sequence 27 ) (20F, 5 0 -GCCGGGCGCTTAGAACA-GAGGCTT-3 0 ; 254F, 5 0 -GTTCTCAGGAAGAAAGA-GATG-3 0 ; 826R, 5 0 -CTTCTCCTCTTCCTCTCG-3 0 ; 1659R, 5 0 -GCCCCAAGCCCTTAATGAAGCAGGA-3 0 ). PCR was performed by using one-tenth of the cDNA reaction as a template, 0.2 mM concentrations of each primer, 25 mM dNTP, and 0.125 U Pfu polymerase (Stratagene Cloning Systems, La Jolla, CA, USA) in a 50-ml total reaction volume. Reactions were conducted for 30 cycles consisting of 30 s at 941C, 5 min at 651C. The PCR products were subjected to the electrophoresis on 1% agarose gels.
Nucleotide sequencing DNA fragments were excised from gels, purified on Suprec-01 (Takara Shuzo Co., Ltd., Otsu, Japan), and reamplified by PCR for 20 cycles consisting of 30 s at 941C and 2 min at 601C by using 2 mM of each primer, 200 mM dNTP, and 0.625 U Taq polymerase (Perkin-Elmer, Norwalk, CT, USA) in a 25-ml total volume. Reaction products were purified by Microcon 100 (Amicon, Inc., Beverly, MA, USA) and directly sequenced by using the AmpliCycle sequencing kit (Perkin-Elmer Corp., Norwalk, CT, USA) and radiolabeled primers according to the manufacturer's instructions. Primers were labeled by using T4 polynucleotide kinase (New England Biolabs, Inc., Beverly, MA, USA) and [g- Inverse PCR High molecular weight DNA was isolated from PBMC as described previously. 62 Genomic DNA was digested with EcoRI (Takara Shuzo Co., Ltd.). Phenol/chloroform extraction was performed to remove residual enzymatic activity, and 0.5 mg of digested DNA was ligated at 161C overnight in a total volume of 500 ml with 4 U of T4 DNA ligase (New England Biolabs, Inc.). The ligated DNA was purified by phenol/chloroform method and eluted in a final volume of 50 ml. Primers were set on the basis of human HS1 cDNA and murine HS1 genomic DNA structure 27, 28 (sense primer, 5 0 -AGCTCTGCTCTCCT CCTCTGTGAGC-3 0 ; antisense primer, 5 0 -CCCATT-TATCCTTCTCCACCCCGTA-3 0 ). The PCR reaction was of 38 cycles (941C for 1 min followed by 38 cycles of 951C for 30 s and 681C for 5 min followed by a termination at 681C for 10 min. The reaction mixture contained 10 ml (approximately 100 ng) of ligated DNA, 7.5 ml of 3.3X GeneAmp XL Buffer II (Perkin-Elmer Corp.), 250 mM dNTPs, 0.5 mM of primer pair, 1.6 U rTth polymerase (Perkin-Elmer Corp.) and 1.875 mM Mg(OAc) 2 . The products were subjected to agarose gel electrophoresis, and approximately 2500 bp fragment was excised from gels, purified, and sequenced.
PCR/single-strand conformation polymorphism (SSCP) analysis Primers for exon-specific PCR for the exon of HS1 gene skipped in the patient were synthesized on the basis of the flanking exon sequence determined by the inverse PCR method (sense primer, 5 0 -CTGACCTCTCTTCTC-CAGCG-3 0 ; antisense primer, 5 0 -GGAAGGAGATCCCTG TGCTA-3 0 ). PCR was performed by using 50 ng of genomic DNA as a template, 0.2 mM concentrations of each primer, 25 mM dNTP including 2 mCi [a-32 P]dCTP (ICN Radiochemicals Inc.), and 0.125 U Taq polymerase (Perkin-Elmer Corp.) in a 5-ml total reaction volume. Reactions were conducted for 30 cycles consisting of 30 s at 941C, 1 min at 651C. The PCR products were subjected to electrophoresis at 251C on 5% non-denaturing acrylamide gels containing 5% glycerol or at 41C without glycerol, using 45 mM Tris-borate, 1 mM EDTA buffer, pH 8.3 and 13V/cm. DNA fragments were visualized by exposing the gels to Kodak XAR film and Fuji imaging plate (Fuji Photo Film Co., Ltd., Kanagawa, Japan). 63 Plasmid construction and transfection HS1 RT-PCR product performed by using RNA from the patient in whom aberrant HS1 was detected was ligated into the pCR2.1. vector (Invitrogen Corp., Carlsbad, CA, USA). The plasmids were restricted with EcoRI (Takara Shuzo Co., Ltd.), subjected to agarose gel electrophoresis. A fragment containing HS1 wild-type cDNA and a fragment of HS1 Dexon A cDNA were excised from gels, purified, and were inserted into the EcoRI site of pCXN-2 mammalian expression vector (kindly provided by Dr J Miyazaki). The sequences of these constructs were confirmed by nucleotide sequencing. These plasmids and control pCXN-2 plasmid were linearized with PvuI (Takara Shuzo Co., Ltd.), and transfected into WEHI-231 cells by electroporation using Gene Pulser apparatus (Bio-Rad Laboratories Inc.) at 250 V, 960 mF, and selected in the presence of 1 mg/ml of G418. Three clones from each transfection were established and used for further analysis. The expression of the transfected cDNA was assessed by Western blot analysis, and each of the stable transformants expressed comparable amounts of HS1 wild-type or HS1 Dexon A to endogenous HS1 of WEHI-231 cells.
Analysis for BCR-induced cell death BCR-induced cell death of wild-type and transfected WEHI-231 cells were investigated by membrane permeability cell death analysis. Cells were resuspended to a concentration of 2.0 Â 10 5 cells/ml in 96-well plate, and left unstimulated or stimulated by adding affinitypurified goat F(ab 0 ) 2 anti-mouse IgM antibody to a final concentration of 1 mg/ml. After 48 h, cells were stained with 1 mg/ml of propidium iodide in PBS, containing 2% FCS/0.05% NaN 3 for 5 min on ice and the percentage of propidium iodide-positive (dead) and -negative (live) cells was determined with FACScan (Becton Dickinson, Mountain View, CA, USA) flow cytometer. Analysis of flow cytometric data was performed using CellQuest software (Becton Dickinson).
Flowcytometric analysis of activated cells and apoptotic cells PBMC from the patient and three control SLE patients were cultured at a concentration of 1 Â 10 7 cells/ml in 24-well plates. Cells were left alone or treated with 20 mg/ml anti-human IgM antibody. After 16 h in culture, cells were harvested. Then cells were washed twice and stained with FITC-conjugated anti-CD69 antibody and PE-conjugated anti-CD19 antibody for the detection of activated cells. On the other hand, cells were stained with FITC-conjugated anti-Annexin V antibody, propidium iodide, and cytochrome-conjugated anti-CD19 antibody for the detection of early apoptotic cells. Cells were washed twice and analyzed on a FACScan (Becton Dickinson).
Statistical analysis
Comparisons between groups were performed using an unpaired Student's t-test.
